HALO

57.75

0.54% 0.31

Dopo l'orario di chiusura: 56.89 -0.86 -1.49%

Halozyme Therapeutics Inc (HALO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HALO Giù? Forum Previsione

Precedente Chiudi:

$57.44

Aprire:

$58

Volume 24 ore:

1.22M

Relative Volume:

0.79

Capitalizzazione di mercato:

$7.35B

Reddito:

$947.36M

Utile/perdita netta:

$392.47M

Rapporto P/E:

19.12

EPS:

3.02

Flusso di cassa netto:

$392.71M

1 W Prestazione:

-0.93%

1M Prestazione:

+3.24%

6M Prestazione:

-7.11%

1 anno Prestazione:

+50.55%

Intervallo 1D:

$57.32

$58.74

Intervallo di 1 settimana:

$56.07

$60.67

Portata 52W:

$37.73

$65.53

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Nome

Halozyme Therapeutics Inc

Settore

Healthcare (1169)

Industria

Biotechnology (678)

Telefono

(858) 794-8889

Indirizzo

12390 EL CAMINO REAL, SAN DIEGO, CA

Dipendente

373

Cinguettio

@halozymeinc

Prossima data di guadagno

2025-02-18

Ultimi documenti SEC

HALO's Discussions on Twitter

Confronta HALO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HALO Halozyme Therapeutics Inc	57.75	7.35B	947.36M	392.47M	392.71M	3.02
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-07	Downgrade	Wells Fargo	Overweight → Equal Weight
2024-09-19	Downgrade	JP Morgan	Overweight → Neutral
2024-06-07	Downgrade	Piper Sandler	Overweight → Neutral
2024-02-29	Iniziato	TD Cowen	Outperform
2023-07-24	Downgrade	Goldman	Buy → Neutral
2023-07-24	Iniziato	H.C. Wainwright	Buy
2023-05-10	Aggiornamento	Piper Sandler	Neutral → Overweight
2023-03-27	Ripresa	Berenberg	Buy
2023-03-16	Downgrade	SVB Securities	Outperform → Market Perform
2022-12-21	Ripresa	Morgan Stanley	Overweight
2022-11-28	Iniziato	Wells Fargo	Overweight
2022-09-09	Iniziato	Morgan Stanley	Overweight
2022-05-23	Iniziato	SVB Leerink	Outperform
2021-06-14	Iniziato	Evercore ISI	Outperform
2021-05-17	Iniziato	SVB Leerink	Outperform
2021-05-11	Downgrade	Piper Sandler	Overweight → Neutral
2021-01-21	Reiterato	The Benchmark Company	Buy
2020-12-17	Iniziato	Berenberg	Buy
2020-09-14	Ripresa	JP Morgan	Overweight
2020-07-01	Iniziato	The Benchmark Company	Buy
2020-02-05	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-01-09	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2020-01-08	Iniziato	Goldman	Buy
2019-11-05	Aggiornamento	Barclays	Underweight → Equal Weight
2018-10-19	Ripresa	Piper Jaffray	Neutral
2018-05-11	Downgrade	Barclays	Equal Weight → Underweight
2018-01-24	Iniziato	Goldman	Neutral
2017-10-16	Reiterato	Piper Jaffray	Overweight
2017-01-06	Downgrade	Citigroup	Buy → Neutral
2016-11-03	Iniziato	Deutsche Bank	Buy
2015-12-04	Iniziato	Wells Fargo	Outperform
2015-11-18	Iniziato	Citigroup	Buy
2015-09-22	Iniziato	Barclays	Overweight
2015-06-22	Reiterato	JP Morgan	Overweight
2015-03-03	Reiterato	UBS	Buy
2015-02-18	Reiterato	MLV & Co	Buy
2015-01-08	Reiterato	MLV & Co	Buy

Mostra tutto

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

07:57 AM

Halozyme projects $1.15B-$1.225B revenue for 2025 with growth from key products - MSN

07:57 AM

Feb 21, 2025

SEC Form 4 filed by PRESIDENT AND CEO Torley Helen - Quantisnow

Feb 21, 2025

Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say - MSN

Feb 21, 2025

Benchmark Reaffirms "Buy" Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat

Feb 21, 2025

Hussman Strategic Advisors Inc. Acquires 31,500 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 21, 2025

HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth - MSN

Feb 21, 2025

Meitav Investment House Ltd. Lowers Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 21, 2025

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - Simply Wall St

Feb 21, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Handelsbanken Fonder AB - MarketBeat

Feb 21, 2025

Rhumbline Advisers Buys 5,833 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 21, 2025

Feb 20, 2025

Assessing Halozyme Therapeutics: Insights From 9 Financial Analysts - Benzinga

Feb 20, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance

Feb 20, 2025

HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat

Feb 20, 2025

Halozyme Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Feb 20, 2025

Kestra Private Wealth Services LLC Sells 9,161 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 20, 2025

Feb 19, 2025

Halozyme Therapeutics (NASDAQ:HALO) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 19, 2025

Halozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Feb 19, 2025

Congress Asset Management Co. Cuts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 19, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 19, 2025

Kornitzer Capital Management Inc. KS Has $10.19 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat

Feb 19, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Holdings Boosted by Convergence Investment Partners LLC - MarketBeat

Feb 19, 2025

Halozyme stock target raised to $78 at JMP Securities - Investing.com India

Feb 19, 2025

Halozyme stock target raised to $78 at JMP Securities By Investing.com - Investing.com Nigeria

Feb 19, 2025